Please login to the form below

Not currently logged in
Email:
Password:

COPD

This page shows the latest COPD news and features for those working in and with pharma, biotech and healthcare.

Is GSK planning to exit the respiratory business?

Is GSK planning to exit the respiratory business?

of the world’s asthma and chronic obstructive pulmonary disease (COPD) medicines.

Latest news

  • Digital Trials Digital Trials

    In a recent COPD simulation, the study protocol, IRB, sensor selection, app development, recruitment, data generation and analysis were all undertaken within a five-month period. ... The devices were selected based on the endpoints that had been

  • UK pharma to work with innovation network on NHS uptake UK pharma to work with innovation network on NHS uptake

    AHSN Network chair Mike Hannay. This specific collaboration encouraged the progression of three projects in Hepatitis C, COPD and mental health all in its first year of operation.

  • Boehringer’s Corsico to be new GSK drug dev leader Boehringer’s Corsico to be new GSK drug dev leader

    However the company has just received bad news from the FDA, the US regulator refusing to approval a licence extension for its respiratory drug Nucala into COPD, citing i nsufficient efficacy

  • AZ prepares to file COPD triple, taking on rival GSK AZ prepares to file COPD triple, taking on rival GSK

    Latest salvo in combination trials competition. AstraZeneca has said it is ready to file for approval of its chronic obstructive pulmonary disease (COPD) triple therapy before the end of the year, ... The data reveals that the drug was better than

  • FDA rejects GSK’s Nucala for COPD FDA rejects GSK’s Nucala for COPD

    the agency reviewers who suggested that GSK had failed to provide sufficient evidence that Nucala was effective in preventing COPD exacerbations. ... Meanwhile, Nucala isn’t the first drug in the IL-5 inhibitor class to run into trouble in COPD.

More from news
Approximately 68 fully matching, plus 201 partially matching documents found.

Latest Intelligence

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

  • Open minds for open innovation Open minds for open innovation

    And a couple of years ago, Novartis and the COPD Foundation’s crowd-shaped project won Communique’s Innovation in Healthcare Communications Award!

  • Significant figures Significant figures

    NTM is a rare progressive, destructive infection that’s normally found in addition to pulmonary diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis or bronchiectasis.

  • The good, the bad and the ugly The good, the bad and the ugly

    Its revenues grew by a further 9% last year. “A large percentage of this growth was driven by Ellipta, but Nucala - a biologic approved for asthma and COPD - also played its ... The category has also seen the recent introduction of a major drug class

  • Asthma: beyond the blue and the brown Asthma: beyond the blue and the brown

    Combine asthma with other respiratory diseases, including chronic obstructive pulmonary disease (COPD), and it contributes to more than 4 million deaths every single year, a stagnated figure that has seen no ... This year, Circassia established a

More from intelligence
Approximately 0 fully matching, plus 36 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Synergy Vision

    In light of today (18th November 2015) being World COPD Day, it’s never too late to raise further awareness on this disease. ... Many people suffer with Chronic Obstructive Pulmonary Disease (COPD), and many others are not aware of signs meaning they

  • Our nursing heroes

    For one chronic obstructive pulmonary disease (COPD) patient in the US, it meant more time with his grandchild. ... I really believe what we do with COPD patients in their own homes as clinical educators is making a big difference to their lives.”  .

  • Big wins for Frontera at the 2016 PM Awards

    This provides healthcare professionals with a life-action experience of what COPD patients go through on a daily basis.  .

  • Frontera wins at IPA Best of Health 2016

    The Silver was awarded for ‘Breathing is everything’, an interactive video created for healthcare professionals that offers a live-action experience of what COPD patients go through on a daily basis.

  • A Bitter Pill?

    as asthma and COPD, where inhalers are the most effective way to deliver medications to the target, this is particularly relevant because success is so dependent on good technique and some

More from PMHub
Approximately 1 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics